398 related articles for article (PubMed ID: 28718062)
1. Update on Biosimilars in Asia.
Tsai WC
Curr Rheumatol Rep; 2017 Aug; 19(8):47. PubMed ID: 28718062
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
3. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
6. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
8. [Biosimilars versus original biologics. Similarities and differences from development to approval].
Windisch J
Z Rheumatol; 2015 Oct; 74(8):672-81. PubMed ID: 26323591
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars: what the oncologist should know.
Thill M; Thatcher N; Hanes V; Lyman GH
Future Oncol; 2019 Apr; 15(10):1147-1165. PubMed ID: 30793950
[TBL] [Abstract][Full Text] [Related]
10. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
11. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
[TBL] [Abstract][Full Text] [Related]
12. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars: A Value Proposition.
de Mora F
BioDrugs; 2019 Aug; 33(4):353-356. PubMed ID: 31175631
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars in IBD: from theory to practice.
Danese S; Bonovas S; Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):22-31. PubMed ID: 27729659
[TBL] [Abstract][Full Text] [Related]
15. Demystifying biosimilars: development, regulation and clinical use.
Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
[TBL] [Abstract][Full Text] [Related]
16. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars in inflammatory bowel disease.
Gargallo CJ; Lué A; Gomollón F
Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice.
Cohen AD; Wu JJ; Puig L; Chimenti S; Vender R; Rajagopalan M; Romiti R; de la Cruz C; Skov L; Zachariae C; Young HS; Foley P; van der Walt JM; Naldi L; Prens EP; Blauvelt A
Br J Dermatol; 2017 Dec; 177(6):1495-1502. PubMed ID: 28646580
[TBL] [Abstract][Full Text] [Related]
20. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
Oza B; Radhakrishna S; Pipalava P; Jose V
J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]